{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.3"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3"},{"groupId":"OG001","value":"15.8"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.1"},{"groupId":"OG001","value":"47.5"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0"},{"groupId":"OG001","value":"24.8"}]}],"title":"PD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"0.9"}]}],"title":"Not Evaluable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"10.7"}]}],"title":"No Tumor Response Evaluation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"335"}],"units":"Participants"}],"description":"BOR was defined as the best response across all time points from randomization until radiologically confirmed PD using RECIST, v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm and normalization of tumor marker level of non-target lesions. PR was defined as having a ≥30% decrease in sum of LD of target lesions. PD was defined as having a ≥20% increase in sum of LD of target lesions and ≥5 mm increase above nadir. SD was defined as small changes that did not meet above criteria.","groups":[{"description":"8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.","id":"OG000","title":"Ramucirumab (IMC-1211B) Plus Paclitaxel"},{"description":"Placebo was administered by IV infusion on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered on Days 1, 8, and 15 of a 28-day cycle.","id":"OG001","title":"Placebo Plus Paclitaxel"}],"paramType":"NUMBER","populationDescription":"All participants according to the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Randomization up to 22.2 months","title":"Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or PD","type":"SECONDARY","unitOfMeasure":"percentage of participants"}